The Vaccine Research Center (VRC), is an intramural division of the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), US Department of Health and Human Services (HHS).

The mission of the VRC is to discover and develop both vaccines and antibody-based products that target infectious diseases.

[6] The founding investigators leading the new center came from a range of scientific disciplines including virology, immunology, structural biology, bioengineering, manufacturing, clinical research and regulatory science.

Office of the Director: Laboratories: Programs: To advance scientific understanding of infectious pathogens and develop investigational biologics, the VRC maintains programs in the following: Key scientific areas[12][11][10]: Primary disease-specific programs: In July 2010, a collaboration between the National Institute of Allergy and Infectious Diseases and officials at the Vaccine Research Center found that two human HIV antibodies, named VRC01 and VRC03, could potentially be used against a wide range of types and mutations of HIV in the design of a preventive HIV vaccine for human use, as well as in the formation of better antiretroviral therapy drug cocktails.

In 2016 research efforts led by Nancy Sullivan at Vaccine Research Center and J. J. Muyembe-Tamfum from the Institut National de Recherche Biomedicale (INRB) in the Democratic Republic of Congo resulted in the discovery of a monoclonal antibody, mAb114, from a survivor from the 1995 Kikwit outbreak of Ebola virus disease.